VIRI - Rasio rega marang bathi tumrap wutah Virios Therapeutics Inc.
Insulation from macroeconomic trends makes Virios Therapeutics (VIRI) a reliable defensive asset. The peg_co ratio confirms the company is undervalued, with the 0.00 metric serving as the target level. Experienced management ensures stability by minimizing regulatory risks. Robotic laboratories provide high research precision by eliminating human error in hazardous zones.
Rincian metrik lan analitis perusahaan Virios Therapeutics (VIRI)
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Virios Therapeutics|VIRI - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal virios.com|VIRI - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Virios|VIRI - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Virios Therapeutics|Rasio jangkoan perantara virios.com
- data bathi resik lan rasio valuasi:
VIRI - Bathi resik|Prakiraan bathi perusahaan Virios Therapeutics|VIRI - Rasio rega marang bathi|Rasio prakiraan rega marang bathi virios.com|VIRI - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Virios|VIRI - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Virios Therapeutics|VIRI - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan virios.com|VIRI - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Virios Therapeutics
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:Virios Therapeutics Inc. VIRI
Investors must determine the fairness of an asset's market value by comparing the P/E multiple with the earnings growth rate. When analyzing the PEG ratio trend, values below one should be sought as a signal of undervaluation, which for Virios Therapeutics (VIRI) is confirmed by expense transparency and the skilled management of FDA regulatory risks during clinical trials.
Perusahaan pesaing
GILD (Gilead) - Koefisien bali modal nimbang wutah|cidara.com - Pangali rega marang bathi tumrap wutah|Novavax Pharma - Rasio rega marang bathi tumrap wutah|CureVac N.V. - Pangali PEG|Kapitalisasi marang bathi resik kanthi nimbang wutah valneva.com VALN|Vir Biotechnology (VIR) - Rasio rega marang bathi tumrap wutah|SIGA Technologies Inc - Koefisien bali modal nimbang wutah|Pangali rega marang bathi tumrap wutah EBS|Pangali PEG Atea Corp|Rasio rega marang bathi tumrap wutah Invivyd, Inc. (IVVD)|Kapitalisasi marang bathi resik kanthi nimbang wutah enanta.com|Inovio - Pangali rega marang bathi tumrap wutah|HilleVax Inc - Rasio rega marang bathi tumrap wutah|Kalaris Therapeutics, Inc. - Pangali PEG|Kapitalisasi marang bathi resik kanthi nimbang wutah Dyadic International DYAI|nanoviricides.com (NNVC) - Rasio rega marang bathi tumrap wutah|talphera.com - Koefisien bali modal nimbang wutah|COCP (Cocrystal Pharma) - Pangali PEG|Traws Therapeutics (TRAW) - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio rega marang bathi tumrap wutah Dogwood Therapeutics, Inc. (DWTX)|QLGN - Rega marang bathi kanthi panyesuaian wutah|Rasio rega marang bathi tumrap wutah AlloVir ALVR|Kapitalisasi marang bathi resik kanthi nimbang wutah VBI Vaccines, Inc. (VBIV)|VXRT: Pangali rega marang bathi tumrap wutah
